Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance  COVID-19 status Phase of research How it helps Latest publication
(+)-oxoturkiyenine
Potential treatment - theoretical effect Natural product Antiviral Aug/22/2020
(-)-beta-Sesquiphellandrene
Potential treatment - theoretical effect Natural product Antiviral Nov/27/2020
(-)-Epicatechin
Potential treatment - theoretical effect Natural product Antiviral Oct/28/2020
(-)-Gallocatechin gallate
Potential treatment - pre-clinical evidence Natural product Antiviral Apr/09/2021
(-)-solenolide A
Potential treatment - theoretical effect Natural product Antiviral Sep/08/2020
(1,3-Dimethylpyrazol-4-yl)-[4-(4-fluorophenyl)piperazin-1-yl]methanone
Potential treatment - theoretical effect Experimental Antiviral Oct/23/2020
(1R,2R)-2-N-(7-Chloroquinolin-4-yl)cyclohexane-1,2-diamine
Potential treatment - theoretical effect Experimental Antiviral Jan/20/2021
(2R,3R,4R,5R)-2-(4-Amino-5-fluoropyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
Potential treatment - pre-clinical evidence Experimental Antiviral Oct/29/2020
(2R,3S,4S,5R,6S)-2-(Hydroxymethyl)-6-[2-methoxy-4-[(E)-prop-1-enyl]phenoxy]oxane-3,4,5-triol
Potential treatment - theoretical effect Natural product Antiviral Aug/14/2020
(2s,3r)-2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-2,3-dihydro-4h-chromen-4-one
Potential treatment - theoretical effect Experimental Antiviral Feb/08/2021
(4Ar,5R,6aS,6aR,6bR,8aS,11R,14aR,14bR)-5-hydroxy-11-(hydroxymethyl)-4,4,6a,6b,8a,11,14b-heptamethyl-2,4a,5,6,6a,7,8,9,10,13,14,14a-dodecahydro-1H-picen-3-one
Potential treatment - theoretical effect Experimental Antiviral Feb/22/2021
(5-Chloropyridin-3-yl) 1H-indole-4-carboxylate
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
(5S,5Ar,8aR,9S)-5-[[(2S,4aR,6R,7S,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
Potential treatment - theoretical effect Experimental Antiviral Sep/17/2020
(E)-4-(4-((5-(4,5-Dimethyl-2-nitrophenyl)furan-2-yl)Methylene)-3-Methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
Potential treatment - theoretical effect Experimental Other treatment Apr/12/2021
(E)-N-[4-[3-Chloro-4-[(3-fluorophenyl)methoxy]anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
Potential treatment - theoretical effect Experimental Antiviral Aug/26/2020
(Recombinant) IL-2
Potential treatment - clinical evidence Experimental Other treatment Jan/18/2021
(Recombinant) IL-3
Potential treatment - pre-clinical evidence Experimental Other treatment Feb/18/2021
(S)-3-((S)-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido) propanamido)-2-oxo-N,4-diphenylbutanamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/10/2021
(S)-5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)chroman-4-one
Potential treatment - theoretical effect Natural product Antiviral Dec/30/2020
1,2,3-triazole-phtalimide compound E40
Potential treatment - theoretical effect Experimental Antiviral Jan/18/2021